Cepheid, a molecular diagnostics company, develops, manufactures, and markets integrated systems for testing in the clinical market; and for application in legacy non-clinical market. Its systems enable molecular testing for organisms and genetic-based diseases by automating manual laboratory procedures. The company offers GeneXpert system that integrates sample preparation in addition to DNA amplification and detection; and SmartCycler system, which integrates DNA amplification and detection to allow rapid analysis of a sample. The GeneXpert system is designed for reference laboratories, hospital central laboratories, and satellite testing locations, such as emergency departments and intensive care units within hospitals and doctors’ offices. Cepheid also provides GeneXpert Infinity System for high volume testing. The company offers tests for the GeneXpert and the SmartCycler systems in the areas of healthcare associated infections, critical infectious disease, sexual health, women’s health, virology, oncology, and genetics. Cepheid sells its products through its direct sales force and through third-party distributors worldwide. It has collaboration agreements with Novartis for the commercialization of a test for monitoring the BCR-ABL gene transcript in peripheral blood specimens; and Life Technologies Corporation to develop reagents for use in the USPS BDS program. The company was founded in 1996 and is headquartered in Sunnyvale, California.

Key Statistics